Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lycorine
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Oral, Intravenous, Subcutaneous
01
Overview
Lycorine is a natural pyrrolo[de]phenanthridine ring-type alkaloid extracted from the Amaryllidaceae plant family. It exhibits a wide range of physiological effects, including anti-cancer, anti-viral, anti-malarial, and anti-inflammatory. Although its exact mechanism of action is not fully understood, lycorine is considered a candidate for anti-inflammatory and anti-cancer treatments. It has been shown to inhibit cell proliferation and metastasis in various cancer types.
- Other names
- LycorinLicorineAmarylineBelamarineNarcissinNSC 401360NSC401360NSC-401360NSC 683873NSC683873NSC-683873
02
Targets
AcetylcholinesterasePDGFRA (Platelet-derived growth factor receptor alpha)TOP1 (DNA Topoisomerase I)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on Lycorine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lycorine.